Samuel G. Moore

Samuel G. Moore

Auto-generated profile, based on publicly available information

Samuel G. Moore

Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Nature
Verified
Journal Article
Open access
PDF file
MGMoTrPAC Study Group
MoTrPAC Study Group
LALead Analysts
Lead Analysts
DADavid Amar
David Amar
NGNicole R. Gay
Nicole R. Gay
PJPierre M. Jean-Beltran
Pierre M. Jean-Beltran
EVElena Volpi
Elena Volpi
Regular exercise promotes whole-body health and prevents disease, but the underlying molecular mechanisms are incompletely understood1–3. Here, the Molecular Transducers of Physical Activity Consortium4 profiled the temporal transcriptome, proteome, metabolome, lipidome, phosphoproteome, acetylproteome, ubiquitylproteome, epigenome and immunome in whole blood, plasma and 18 solid tissues in male and female Rattus norvegicus over eight weeks of endurance exercise training. The resulting data compendium encompasses 9,466 assays across 19 tissues, 25 molecular platforms and 4 training time points. Thousands of shared and tissue-specific molecular alterations were identified, with sex differences found in multiple tissues. Temporal multi-omic and multi-tissue analyses revealed expansive biological insights into the adaptive responses to endurance training, including widespread regulation of immune, metabolic, stress response and mitochondrial pathways. Many changes were relevant to human health, including non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular health and tissue injury and recovery. The data and analyses presented in this study will serve as valuable resources for understanding and exploring the multi-tissue molecular effects of endurance training and are provided in a public repository (https://motrpac-data.org/).

15 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
PPP. Pradhan
P. Pradhan
RTR. Toy
R. Toy
NJN. Jhita
N. Jhita
AAA. Atalis
A. Atalis
BPB. Pandey
B. Pandey
KRK. Roy
K. Roy
TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate immune responses to particle-delivered MPLA and CpG.

26 March 2022 in Limnology and Oceanography
Verified
Journal Article
Closed access
EBEmily R. Brown
Emily R. Brown
SMSam G. Moore
Sam G. Moore
DGDavid A Gaul
David A Gaul
Julia KubanekJulia Kubanek
Julia Kubanek

29 June 2021 in ChemBioChem
Verified
Journal Article
Open access
PDF file
IMIPSITA MOHANTY
IPSITA MOHANTY
NNNguyet A. Nguyen
Nguyet A. Nguyen
SMSamuel G. Moore
Samuel G. Moore
JBJason S. Biggs
Jason S. Biggs
DGDavid A Gaul
David A Gaul
VAVinayak Agarwal
Vinayak Agarwal
Proline‐rich macrocyclic peptides (PRMPs) are natural products present in geographically and phylogenetically dispersed marine sponges. The large diversity and low abundance of PRMPs in sponge metabolomes precludes isolation and structure elucidation of each individual PRMP congener. Here, using standards developed via biomimetic enzymatic synthesis of PRMPs, a mass spectrometry‐based workflow to sequence PRMPs was developed and validated to reveal that the diversity of PRMPs in marine sponges is much greater than that has been realized by natural product isolation‐based strategies. Findings are placed in the context of diversity‐oriented transamidative macrocyclization of peptide substrates in sponge holobionts.

27 February 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
SSSamyukta Sah
Samyukta Sah
OBOlatomiwa Bifarin
Olatomiwa Bifarin
SMSamuel G. Moore
Samuel G. Moore
DGDavid A Gaul
David A Gaul
HCHyewon Chung
Hyewon Chung
Facundo M. FernándezFacundo M. Fernández
Facundo M. Fernández
Background: Distinguishing ovarian cancer from other gynecological malignancies is crucial for patient survival yet hindered by non-specific symptoms and limited understanding of ovarian cancer pathogenesis. Accumulating evidence suggests a link between ovarian cancer and deregulated lipid metabolism. Most studies have small sample sizes, especially for early-stage cases, and lack racial/ethnic diversity, necessitating more inclusive research for improved ovarian cancer diagnosis and prevention. Methods: Here, we profiled the serum lipidome of 208 ovarian cancer, including 93 early-stage patients with ovarian cancer and 117 nonovarian cancer (other gynecological malignancies) patients of Korean descent. Serum samples were analyzed with a high-coverage liquid chromatography high-resolution mass spectrometry platform, and lipidome alterations were investigated via statistical and machine learning (ML) approaches. Results: We found that lipidome alterations unique to ovarian cancer were present in Korean women as early as when the cancer is localized, and those changes increase in magnitude as the diseases progresses. Analysis of relative lipid abundances revealed specific patterns for various lipid classes, with most classes showing decreased abundance in ovarian cancer in comparison with other gynecological diseases. ML methods selected a panel of 17 lipids that discriminated ovarian cancer from nonovarian cancer cases with an AUC value of 0.85 for an independent test set. Conclusions: This study provides a systemic analysis of lipidome alterations in human ovarian cancer, specifically in Korean women. Impact: Here, we show the potential of circulating lipids in distinguishing ovarian cancer from nonovarian cancer conditions.

22 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JKJames M Kelvin
James M Kelvin
DZDan Y Zhang
Dan Y Zhang
EWEvelyn K Williams
Evelyn K Williams
SMSamuel G Moore
Samuel G Moore
LBLacey A Birnbaum
Lacey A Birnbaum
EDErik C Dreaden
Erik C Dreaden
Advances in multiagent chemotherapy have led to recent improvements in overall survival for patients with acute lymphoblastic leukemia (ALL); however, a significant fraction do not respond to frontline chemotherapy or later relapse with recurrent disease, after which long-term survival rates remain low. To address the challenge of developing new, effective treatment options for these patients, we conducted a series of high-throughput combination drug screens to identify chemotherapies that synergize in a lineage-specific manner with MRX-2843, a small molecule dual MERTK and FLT3 kinase inhibitor currently in clinical testing for treatment of relapsed/refractory leukemias and solid tumors. Using experimental and computational approaches, we found that MRX-2843 synergized strongly – and in a ratio-dependent manner – with vincristine chemotherapy to inhibit T-ALL cell expansion and, based on these findings, we developed multiagent lipid nanoparticle formulations of these drugs that not only constitutively maintained ratiometric drug synergy following T-ALL cell delivery, but also improved anti-leukemic activity following drug encapsulation. To determine the clinical relevance of these combination drug formulations and the therapeutic impact of ratiometric drug synergy, we compared the efficacy of lipid nanoparticles comprising synergistic, additive, and antagonistic ratios of MRX-2843 and vincristine, and observed that trends in in vitro synergy were directly recapitulated in primary T-ALL patient samples. Together, these findings present a systematic approach to high-throughput combination drug screening and multiagent drug delivery that maximizes the therapeutic potential of combined MRX-2843 and vincristine in T-ALL. This broadly generalizable approach could lead to the development of constitutively synergistic combination products for the treatment of cancer and other diseases.